[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2680604C - Forme triol de rosuvastatine - Google Patents

Forme triol de rosuvastatine Download PDF

Info

Publication number
CA2680604C
CA2680604C CA2680604A CA2680604A CA2680604C CA 2680604 C CA2680604 C CA 2680604C CA 2680604 A CA2680604 A CA 2680604A CA 2680604 A CA2680604 A CA 2680604A CA 2680604 C CA2680604 C CA 2680604C
Authority
CA
Canada
Prior art keywords
rosuvastatin
triol
ester
calcium
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2680604A
Other languages
English (en)
Other versions
CA2680604A1 (fr
Inventor
Valerie Niddam-Hildesheim
Anna Balanov
Irena Veinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CA2680604A1 publication Critical patent/CA2680604A1/fr
Application granted granted Critical
Publication of CA2680604C publication Critical patent/CA2680604C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2680604A 2007-03-13 2008-03-13 Forme triol de rosuvastatine Expired - Fee Related CA2680604C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90691407P 2007-03-13 2007-03-13
US60/906,914 2007-03-13
US91846607P 2007-03-15 2007-03-15
US60/918,466 2007-03-15
PCT/US2008/003470 WO2008112317A2 (fr) 2007-03-13 2008-03-13 Forme triol de rosuvastatine

Publications (2)

Publication Number Publication Date
CA2680604A1 CA2680604A1 (fr) 2008-09-18
CA2680604C true CA2680604C (fr) 2012-08-07

Family

ID=39650560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2680604A Expired - Fee Related CA2680604C (fr) 2007-03-13 2008-03-13 Forme triol de rosuvastatine

Country Status (8)

Country Link
EP (1) EP2121631A2 (fr)
JP (1) JP5330225B2 (fr)
KR (1) KR100945760B1 (fr)
BR (1) BRPI0803085A2 (fr)
CA (1) CA2680604C (fr)
IL (1) IL200449A0 (fr)
MX (1) MX2008014552A (fr)
WO (1) WO2008112317A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575343B2 (en) * 2010-06-07 2013-11-05 Pharmathen S.A. Process for the preparation of a propenal intermediate and derivatives thereof
CN112782333B (zh) * 2020-12-25 2022-07-12 石家庄四药有限公司 一种匹伐他汀异丙基叔丁酯非对映异构体的hplc检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244844B2 (en) * 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin

Also Published As

Publication number Publication date
EP2121631A2 (fr) 2009-11-25
JP5330225B2 (ja) 2013-10-30
JP2009519353A (ja) 2009-05-14
MX2008014552A (es) 2009-03-09
BRPI0803085A2 (pt) 2011-08-30
KR20090010195A (ko) 2009-01-29
CA2680604A1 (fr) 2008-09-18
WO2008112317A2 (fr) 2008-09-18
WO2008112317A3 (fr) 2008-11-06
IL200449A0 (en) 2010-04-29
KR100945760B1 (ko) 2010-03-08

Similar Documents

Publication Publication Date Title
US7741482B2 (en) Reference standard for characterization of rosuvastatin
US7566782B2 (en) Process for the preparation of rosuvastatin
US20070037979A1 (en) Preparation of rosuvastatin
CN103459381B (zh) 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸晶型及其生产方法
MX2007010138A (es) Preparacion de rosuvastatina.
CA2680604C (fr) Forme triol de rosuvastatine
CA2725052C (fr) Procede de preparation de la rosuvastatine calcique et de ses intermediaires
US7851624B2 (en) Triol form of rosuvastatin and synthesis of rosuvastatin
JP2010501643A (ja) 薄膜蒸発及び化学的手法によるロスバスタチン中間体の精製
EP2334667A1 (fr) Procédé de préparation d acétonide de rosuvastatine calcique
Schneider et al. Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection
CN101631777A (zh) 罗苏伐他汀的三醇形式

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150313